Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the sale, the chief executive officer now owns 143,603 shares in the company, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total transaction of $782,556.25.

Vera Therapeutics Trading Down 12.3 %

NASDAQ VERA traded down $5.17 on Friday, hitting $37.02. 944,198 shares of the company were exchanged, compared to its average volume of 531,400. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a twelve month low of $14.20 and a twelve month high of $51.61. The company's 50 day moving average price is $45.41 and its 200-day moving average price is $40.97. The firm has a market capitalization of $2.34 billion, a P/E ratio of -14.18 and a beta of 1.15.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on VERA. Evercore ISI upgraded shares of Vera Therapeutics to a "strong-buy" rating in a research report on Monday, September 16th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Wedbush boosted their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research report on Friday, November 8th. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target on the stock. Finally, Guggenheim boosted their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and an average price target of $63.50.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Vera Therapeutics by 6.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company's stock valued at $5,981,000 after buying an additional 9,854 shares in the last quarter. TD Asset Management Inc grew its stake in shares of Vera Therapeutics by 18.4% in the 2nd quarter. TD Asset Management Inc now owns 154,338 shares of the company's stock valued at $5,584,000 after buying an additional 24,000 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Vera Therapeutics by 202.4% in the 2nd quarter. Victory Capital Management Inc. now owns 33,707 shares of the company's stock valued at $1,220,000 after buying an additional 22,560 shares in the last quarter. Arizona State Retirement System boosted its position in Vera Therapeutics by 14.4% during the second quarter. Arizona State Retirement System now owns 9,907 shares of the company's stock worth $358,000 after purchasing an additional 1,250 shares during the period. Finally, American Century Companies Inc. bought a new stake in Vera Therapeutics during the second quarter worth approximately $14,015,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.